Building What Matters: Why Advanced Diagnostics Must Create Jobs, Not Just Data By Anjo De Heus

Building What Matters: Why Advanced Diagnostics Must Create Jobs, Not Just Data

What began as a collaboration around diagnostic innovation has evolved into something much larger — and much more necessary.

Not another pilot.
Not another report.
Not another promise.

But a serious execution effort to bring advanced diagnostics to people — while creating jobs, skills, and economic participation along the way.

This distinction matters.

The Problem We Keep Avoiding

Across Africa, innovation is everywhere — but access is not.

Advanced diagnostics exist.
Molecular tools exist.
Digital health platforms exist.

Yet for hundreds of millions of people in Africa:

  • diagnostics remain centralized or unavailable
  • healthcare jobs are scarce
  • manufacturing is offshore
  • systems are fragmented
  • innovation arrives without ownership

Too often, technologies are deployed on top of missing systems rather than used to build them.

And when that happens, even good technology fails to deliver dignity, resilience, or long-term impact.

Our Starting Point Was Simple

If diagnostics are truly life-changing, they must do more than detect disease.

They must:

  • create local employment
  • build national capability
  • strengthen health sovereignty
  • support economic participation, especially for youth and women

This belief sits at the heart of our collaboration.

Oasis Diagnostics brings decentralized, saliva-based molecular technology designed for real-world conditions.

Oludent Health International brings the clinical, telehealth, digital workflow, and education layer — with a deep commitment to training and capacity building.

360Disruption provides the execution, government alignment, and system integration required to move from innovation to national-scale deployment.

Together, we are not selling products.
We are building delivery systems.

Diagnostics as an Economic Engine

Diagnostics are often treated as a cost line in healthcare.

We see them differently.

When structured correctly, diagnostics become:

  • job creators (operators, coordinators, technicians, logistics)
  • entrepreneurship platforms (service providers, local enterprises)
  • manufacturing anchors
  • data foundations owned by nations, not extracted from them

This is where health and economics meet.

And this is where many well-intentioned innovations fall short — not because they lack scientific merit, but because they lack execution architecture.

Why We Are Opening This Conversation

As this initiative gains traction, one thing has become clear:
we cannot — and should not — build this alone.

Across the United States, there are extraordinary bio-tech, health-tech, diagnostic, and platform companies developing technologies that could change lives — if they were deployed within the right systems.

We are therefore deliberately opening this effort to aligned third parties who share three principles:

  1. Access before intelligence
  2. Jobs before dashboards
  3. Systems before pilots

This is not an accelerator.
Not a marketplace.
Not a branding exercise.

It is a consortium of execution.

What Joining This Consortium Really Means

It means being willing to:

  • adapt technology for real operating environments
  • support local skills transfer and training
  • think beyond single-country pilots
  • treat governments as partners, not customers
  • measure success in jobs, access, and resilience — not just installs

If your technology strengthens diagnostics, screening, care coordination, manufacturing, or health system delivery, there is a place for you — provided the purpose aligns.

The Goal Is Not Expansion. It Is Impact.

Africa does not need more solutions hunting for problems.
It needs builders willing to do the hard work of implementation.

Our intention is clear:
To bring advanced diagnostics to the people, while building the economic and human systems that allow those diagnostics to matter.

If that resonates with you, there is likely a reason.

And the conversation is open.

Real innovation is not what you invent.
It’s what you’re willing to build — together — where it matters most.

Comments

Post a Comment

Popular posts from this blog

Launching a Healthtech Venture in the UAE: A Strategic Guide by 360Disruption

Image
A Strategic Launch Guide by @360disruption The United Arab Emirates (UAE) is quickly becoming one of the most promising launchpads for global healthtech innovation. With forward-thinking leadership, robust infrastructure, and a commitment to becoming a regional healthcare powerhouse, the UAE offers unparalleled opportunities for startups and scale-ups alike. At 360Disruption, we’ve helped companies from the U.S. and Europe navigate this ecosystem — and this guide captures what it takes to enter and scale across the Emirates. The Rise of Healthtech in the UAE: Why It Matters Across the UAE, government-driven healthcare modernization is accelerating. From Abu Dhabi’s academic health initiatives to Dubai’s smart health infrastructure , the country is positioning itself as a global healthtech hub. Key drivers include: Dubai Academic Health Corporation (DAHC) and Dubai Health Authority (DHA) initiatives such as NABIDH (Unified Medical Records) and Sheryan (Smart Licensing). Abu Dhabi...
Read more

Why 360Disruption Is the Partner of Choice for Health-tech Expansion in the Gulf

Image
In today’s competitive global health-tech landscape, entering new markets requires more than a regulatory checklist or a polished investor deck. It requires local traction, commercial validation, and trusted partnerships that can turn plans into performance. That’s where 360Disruption comes in. At 360Disruption, we don’t offer advisory in a vacuum. We execute. Whether you’re a U.S.-based company seeking to expand to the UAE, or a visionary startup looking for a trusted partner to bring your solution to life, we offer a pathway grounded in reality and built for scale Three Paths to Market Entry. One Strategic Engine. Every company we work with is different. Some are still testing product-market fit. Others are ready to scale. A few simply need the right on-the-ground team to carry the commercial flag. That’s why we built our platform around three adaptable tracks: 1. Incubation We work with early-stage companies or first-time entrants into the region to de-risk market entry, validate lo...
Read more

Why the UAE’s Medical Device Classification System is a Game-Changer for U.S. Healthtech Companies

Image
Why the UAE’s Medical Device Classification System is a Game-Changer for U.S. Healthtech Companies   The United Arab Emirates (UAE) has quietly built one of the world’s most innovation-friendly pathways for medical device companies—and now, more than ever, U.S.-based healthtech startups and scaleups should take notice. Unlike the FDA’s formal and risk-heavy classification system, the UAE’s Ministry of Health and Prevention (MOHAP) offers a flexible, product-specific, and internationally harmonized framework that accelerates market access, reduces cost, and creates entry into a health-conscious, tech-forward region. This is not just an alternative to the U.S. regulatory maze—it’s a springboard into the broader Middle East, Africa, and Asia.   UAE vs. FDA: Key Differences at a Glance Criteria FDA (USA) MOHAP / UAE Classification Class I, II, III Class I, IIa, IIb, III (EU MDR aligned) Approach Risk-based Risk-based + product-specific Timeline 12–36 months Weeks to classification...
Read more